The Pharma Data

NOVEMBER 8, 2020

R&D pipeline continues to drive future value through innovation and differentiated therapies including expected upcoming approval of Tirbanibulin. Based on the solid year to date performance Almirall is reiterating its guidance for FY 2020. Financial highlights (€ million). .

Licensing 52

Licensing Licensing Production Marketing 52

Agency IQ

MARCH 7, 2024

government recently extended that recognition through 2028 for medical devices and 2030 for IVDs. Certain IVDs will be treated differently; companion diagnostics used with drug therapies would have to include the international non-proprietary name (INN) of the medicine the test is used with. There were myriad reasons for the extension.

Regulations 40

Regulations International Production Government 40

DrugBank

AUGUST 9, 2024

trillion by 2028. These new therapies have demonstrated significant LDL cholesterol reductions, but their high cost remains a barrier to widespread adoption. billion by 2028, demonstrating the urgent need for effective treatments. This can significantly impact a company's ability to recoup its R&D investment.

Pharmaceuticals 98

Pharmaceuticals Research Pharmaceutical Companies Clinical Trials 98

Agency IQ

MAY 17, 2024

The Creating Hope Reauthorization Act would extend the expiration date of the program for another four years , from September 30, 2024 to September 30, 2028. The Give Kids a Chance Act extends the RACE for Children Act’s requirements one major step farther , applying them to combination therapies in addition to single-drug therapies.

FDA 40

FDA Disease FDA Approval Production 40

The Pharma Data

JUNE 11, 2025

The expanded agreement, which now stretches the collaboration through at least 2028, marks a new chapter in the two organizations’ efforts to harness cutting-edge genomic research, high-throughput screening platforms, and translational science to deliver precision medicines that could alter the course of chronic cardiovascular diseases.

Drug Research 40

Drug Research Research Small Molecule Drugs 40

Codon

SEPTEMBER 29, 2024

It suggested that, in the future, certain classes of drugs, specifically genetic therapies, could be screened entirely virtually via models of life. 2028 Over the next year, the scientific community ferociously interrogated the model. Of particular interest was how genetic therapies were delivered.

Engineering 145

Engineering Virus DNA Therapies 145

The Pharma Data

NOVEMBER 4, 2020

“We are excited to be nearing the EMA’s regulatory decision on VASCEPA and are busy preparing for our anticipated commercial launch in Europe, where there is a large and growing opportunity for Amarin to bring this proven effective therapy to the millions of patients at high risk for cardiovascular events. 500 mg/dL) hypertriglyceridemia.

Production 40

Production Trials Disease FDA 40

The Pharma Data

SEPTEMBER 15, 2020

27 key programs highlighted, including assets that could potentially contribute revenue by 2025 and others in the 2026-2028 time frame. Based on the acceptable safety profile and the favorable immune response data, including the 4th dose response data, Pfizer received Breakthrough Therapy Designation.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52

New Drug Approvals

APRIL 27, 2025

New Drug Therapy Approvals 2024 (PDF). Flurpiridaz F 18 WeightAverage: 367.84 3] Flurpiridaz ( 18 F) It is given by intravenous injection. [3] 3] Flurpiridaz ( 18 F) was approved for medical use in the United States in September 2024. [3] 2008 ; Nagel 2014 ) Briefly, to a mixture of mucochloric acid ( 1 ) (1.18 mmol) and Na 2 CO 3 (0.33

FDA 57

FDA Clinical Trials FDA Approval Disease 57